HRP20220898T1 - Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima - Google Patents
Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima Download PDFInfo
- Publication number
- HRP20220898T1 HRP20220898T1 HRP20220898TT HRP20220898T HRP20220898T1 HR P20220898 T1 HRP20220898 T1 HR P20220898T1 HR P20220898T T HRP20220898T T HR P20220898TT HR P20220898 T HRP20220898 T HR P20220898T HR P20220898 T1 HRP20220898 T1 HR P20220898T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound
- substituted
- groups
- independently
- Prior art date
Links
- 108010040201 Polymyxins Proteins 0.000 title claims 6
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000004474 heteroalkylene group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 239000013543 active substance Substances 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- -1 tricarcillin Chemical compound 0.000 claims 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 6
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 3
- 235000008206 alpha-amino acids Nutrition 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000007649 L alpha amino acids Chemical class 0.000 claims 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical group CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 2
- 229960003644 aztreonam Drugs 0.000 claims 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 2
- 229960004675 fusidic acid Drugs 0.000 claims 2
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229960002260 meropenem Drugs 0.000 claims 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 229960002950 novobiocin Drugs 0.000 claims 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims 2
- 229960001019 oxacillin Drugs 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- 229960004089 tigecycline Drugs 0.000 claims 2
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 claims 2
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 claims 1
- KEDAXBWZURNCHS-GPODMPQUSA-N (4r,5s,6s)-3-[(3s,5s)-5-[(3s)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound O=C([C@@H]1C[C@@H](CN1C)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)N1CC[C@H](NC(=O)CN=C(N)N)C1 KEDAXBWZURNCHS-GPODMPQUSA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 1
- 229930182832 D-phenylalanine Natural products 0.000 claims 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 claims 1
- 108010053950 Teicoplanin Proteins 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- KLFSEZJCLYBFKQ-WXYNYTDUSA-N [(3s)-3-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCC1=CC(=O)C(O)=CN1O KLFSEZJCLYBFKQ-WXYNYTDUSA-N 0.000 claims 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 1
- PENDGIOBPJLVBT-HMMOOPTJSA-N abt-773 Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(C)OC\C=C\C=1C=C2C=CC=CC2=NC=1)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O PENDGIOBPJLVBT-HMMOOPTJSA-N 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 229960003169 biapenem Drugs 0.000 claims 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims 1
- 229960003669 carbenicillin Drugs 0.000 claims 1
- 229950010329 cethromycin Drugs 0.000 claims 1
- HLFSMUUOKPBTSM-ISIOAQNYSA-N chembl1951095 Chemical compound C([C@H]1C[C@H]2[C@@H](C(=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C1C(=O)C1=C2O)O)N(C)C)C1=C(F)C=C2NC(=O)CN1CCCC1 HLFSMUUOKPBTSM-ISIOAQNYSA-N 0.000 claims 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229960003326 cloxacillin Drugs 0.000 claims 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims 1
- 229960002488 dalbavancin Drugs 0.000 claims 1
- 108700009376 dalbavancin Proteins 0.000 claims 1
- 229950006412 delafloxacin Drugs 0.000 claims 1
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 claims 1
- 229960000895 doripenem Drugs 0.000 claims 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 229950004877 eravacycline Drugs 0.000 claims 1
- 229960002770 ertapenem Drugs 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960004273 floxacillin Drugs 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 235000014705 isoleucine Nutrition 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960000515 nafcillin Drugs 0.000 claims 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229950004150 omadacycline Drugs 0.000 claims 1
- JEECQCWWSTZDCK-IQZGDKDPSA-N omadacycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O JEECQCWWSTZDCK-IQZGDKDPSA-N 0.000 claims 1
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims 1
- 229960001607 oritavancin Drugs 0.000 claims 1
- 108010006945 oritavancin Proteins 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 229950011346 panipenem Drugs 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 1
- 229960000885 rifabutin Drugs 0.000 claims 1
- SGHWBDUXKUSFOP-KYALZUAASA-N rifalazil Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N=C2C(=O)C=3C(O)=C4C)C)OC)C4=C1C=3C(NC1=C(O)C=3)=C2OC1=CC=3N1CCN(CC(C)C)CC1 SGHWBDUXKUSFOP-KYALZUAASA-N 0.000 claims 1
- 229950005007 rifalazil Drugs 0.000 claims 1
- 229960002599 rifapentine Drugs 0.000 claims 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 1
- 229960003040 rifaximin Drugs 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 229950008588 solithromycin Drugs 0.000 claims 1
- 229960001608 teicoplanin Drugs 0.000 claims 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims 1
- 229960005240 telavancin Drugs 0.000 claims 1
- 108010089019 telavancin Proteins 0.000 claims 1
- 229960003250 telithromycin Drugs 0.000 claims 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims 1
- 229950003816 tomopenem Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Polimiksinski spoj namijenjen upotrebi u postupku liječenja ili profilakse, u kombinaciji s aktivnim sredstvom, ili polimiksinski spoj i aktivno sredstvo namijenjeni upotrebi u postupku liječenja ili profilakse, ili aktivno sredstvo namijenjeno upotrebi u postupku liječenja ili profilakse, u kombinaciji s polimiksinskim spojem,
primjerice kada su namijenjeni upotrebi u postupku liječenja mikrobne infekcije,
naznačeni time što se aktivno sredstvo bira iz skupine koju čine:
rifampicin, rifabutin, rifalazil, rifapentin, te rifaksimin;
oksacilin, meticilin, ampicilin, kloksacilin, karbenicilin, piperacilin, trikarcilin, flukloksacilin, te nafcilin;
azitromicin, klaritromicin, eritromicin, telitromicin, cetromicin, te solitromicin;
aztreonam i BAL30072;
meropenem, doripenem, imipenem, ertapenem, biapenem, tomopenem, te panipenem;
tigeciklin, omadaciklin, eravaciklin, doksiciklin, te minociklin;
ciprofloksacin, levofloksacin, moksifloksacin, te delafloksacin;
fuzidična kiselina;
novobiocin;
teikoplanin, telavancin, dalbavancin, te oritavancin,
i njihove farmaceutski prihvatljive soli i solvati; i
polimiksinski spoj je spoj formule (I):
[image]
,
i njegove farmaceutski prihvatljive soli i solvati,
gdje:
-X- je -C(O)-, -NHC(O)-, -OC(O)-, -CH2- ili -SO2-, primjerice gdje je -X- -C(O)-; i
-R1 zajedno s karbonilnom skupinom i dušikom na položaju alfa u odnosu na ugljik na kojeg je vezan, je fenilalaninski, leucinski ili valinski ostatak, primjerice fenilalaninski ili leucinski ostatak, poput d-fenilalanina ili d-leucina;
-R2 zajedno s karbonilnom skupinom i dušikom na položaju alfa u odnosu na ugljik na kojeg je vezan, je leucinski, treoninski, iso-leucinski, fenilalaninski, valinski ili nor-valinski ostatak, primjerice leucinski ili treoninski ostatak, poput l-leucina ili l-treonina;
-R3 zajedno s karbonilnom skupinom i dušikom na položaju alfa u odnosu na ugljik na kojeg je vezan, je treoninski ili leucinski ostatak, primjerice treoninski ostatak, poput l-treonina;
-R4 je C1-6 alkil supstituiran s jednom hidroksilnom skupinom ili jednom skupinom amino, primjerice gdje je -R4 zajedno s karbonilnom skupinom i dušikom na položaju alfa u odnosu na ugljik na kojeg je vezan, α,γ-diaminomaslačna kiselina (Dab), serinski ostatak, treoninski ostatak, lizinski ostatak, ornitinski ostatak, ili α,β-diaminopropionska kiselina (Dap), poput Dab, poput l-Dab;
-A- je kovalentna veza ili aminokiselina, poput α-aminokiseline;
-R5 je G-L2-L1-;
-G se bira između:
C2-12 alkil,
C5-12 aril,
C3-10 cikloalkil;
-L1- je kovalentna veza, C1-12 alkilen ili C2-12 heteroalkilen,
-L2- je kovalentna veza ili C4-10 heterociklilen,
uz uvjet da -L1- nije C1-12 alkilen kada je -G C2-12 alkil, te
G-L2-L1- je supstituiran s:
(i) jednom, dvije ili tri hidroksilne skupine, ili
(ii) jednom, dvije ili tri skupine -NR6R7, ili
(iii) jednom ili dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine,
uz uvjet da su (i), (ii) i (iii) izborni supstituenti kada je -L1- C2-12 heteroalkilen koji sadrži dušik i/ili -L2- je C4-10 heterociklilen koji sadrži dušik, ili
-R5 je D-L1-, gdje je -D C4-10 heterociklil, -L1- je definiran kao gore, a O-L1- je supstituiran s:
(i) jednom, dvije ili tri hidroksilne skupine, ili
(ii) jednom, dvije ili tri skupine -NR6R7, ili
(iii) jednom ili dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine,
uz uvjet da su (i), (ii) i (iii) izborni supstituenti kada je -L1- C2-12 heteroalkilen koji sadrži dušik i/ili je -D C4-10 heterociklil koji sadrži dušik;
svaki -R6 je neovisno vodik ili C1-4 alkil;
svaki -R7 je neovisno vodik ili C1-4 alkil; ili
-NR6R7 je gvanidinska skupina; ili
kada je -G C3-10 cikloalkil ili C5-12 aril, -R6 i -R7 zajedno s atomom dušika iz C4-10 heterocikla; i
kada je arilna skupina je prisutna u -R5 taj može biti neovisno supstituiran s jednim ili više supstituenata koje se bira između -C1-10 alkila, poput -C1-4 alkila, halogena, -CN, -NO2, -CF3, -NR10C(O)R10, -OCF3, -CON(R10)2, -COOR9, -OCOR10, -NR10COOR10, -OCON(R10)2, -NR10CON(R10)2, -OR9, -SR9, -NR10SO2R10, -SO2N(R10)2 i -SO2R10, gdje je svaki -R9 neovisno -C1-10 alkil, poput -C1-4 alkila, a svaki -R10 je neovisno -H ili -C1-10 alkil, poput -C1-4 alkil; i
kada je alkilna, cikloalkilna ili heterociklilna skupina prisutna u -R5 taj može biti neovisno supstituiran s jednim ili više supstituenata koje se bira između -C1-10 alkila, poput -C1-4 alkila, halogena, -CN, -NO2, -CF3, -C(O)R10, -NR10C(O)R10, -OCF3, -CON(R10)2, -COOR9, -OCOR10, -NR10COOR10, -OCON(R10)2, -NR10CON(R10)2, -OR9, -SR9, -NR10SO2R10, -SO2N(R10)2 i -SO2R10, gdje je svaki -R9 neovisno -C1-10 alkil, poput -C1-4 alkila, a svaki -R10 je neovisno -H ili -C1-10 alkil, poput -C1-4 alkila, osim što alkil nije supstituiran s alkilom;
-R8 je metil ili vodik, primjerice metil;
uz uvjet da spoj formule (I) nije spoj u kojem -X- i -R5 zajedno tvore l-α-aminokiselinu, poput Lys, Arg, Dap, Ser, Phe, Trp, Leu, Ala, α,γ-diaminomaslačne kiseline (Dab) ili α,β-diaminopropionske kiseline (Dap), izborno zajedno s Dgp i Abu.
2. Polimiksinski spoj formule (II), naznačen time što ga prikazuje formula:
[image]
,
i njegove farmaceutski prihvatljive soli i solvati,
gdje -X-, -R1, -R2, -R3, -R4, -R6, -R7, -R8 imaju ista značenja kao -X-, -R1, -R2, -R3, -R4, -R6, -R7, -R8 u patentnom zahtjevu 1, osim kada su dodatno definirani kao niže;
-A- je kovalentna veza ili aminokiselina, poput α-aminokiseline; i
spoj se bira između (IIa) do (IIe) i (IIg) niže:
(IIg) koji je spoj formule (II) gdje:
-R4 je C1 alkil supstituiran s jednom skupinom amino, ili C3-5 alkil supstituiran s jednom skupinom amino; i
-R5 ima isto značenje kao -R5 u patentnom zahtjevu 1;
(IIa) koji je spoj formule (II) gdje:
-R5 je G-L2-L1-, a -G je C5-12 aril,
-L1- je kovalentna veza, C1-12 alkilen ili C2-12 heteroalkilen,
-L2- je kovalentna veza ili C4-10 heterociklilen,
-R5 je supstituiran s:
(i) jednom, dvije ili tri hidroksilne skupine, ili
(ii) jednom, dvije ili tri skupine -NR6R7, ili
(iii) jednom ili dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine,
uz uvjet da su (i), (ii) i (iii) izborni supstituenti kada je -L1- C2-12 heteroalkilen koji sadrži dušik i/ili -L2- je C4-10 heterociklilen koji sadrži dušik, te
arilna skupina može biti supstituirana s jednim ili više supstituenata koje se bira između C1-10 alkil, poput -C1-4 alkila, halogena, -CN, -NO2, -CF3, -NR10C(O)R10, -OCF3, -CON(R10)2, -COOR9, -OCOR10, -NR10COOR10, -OCON(R10)2, -NR10CON(R10)2, -OR9, -SR9, -NR10SO2R10, -SO2N(R10)2 i -SO2R10, gdje je svaki -R9 neovisno C1-10 alkil, poput -C1-4 alkila, a svaki -R10 je neovisno -H ili C1-10 alkil, poput -C1-4 alkila;
(IIe) koji je spoj formule (II) gdje:
-A- je aminokiselina, poput α-aminokiseline, koju se primjerice bira iz skupine koju čine Dab, Dap, Lys, Arg, Dap, Ser, Phe, Trp, Leu, Ala, ornitin ili nor-valin, poput Dab, Dap, Thr, Ser ili Lys, poput Dab, poput l-Dab; i
-R5 ima isto značenje kao -R5 u patentnom zahtjevu 1;
(IIc) koji je spoj formule (II) gdje:
-R5 je G-L2-L1-, gdje je -G C3-10 cikloalkil ili C2-12 alkil,
-L1- je kovalentna veza ili C1-12 alkilen,
-L2- je kovalentna veza,
uz uvjet da -L1- nije C1-12 alkilen kada je -G C2-12 alkil, -R5 je supstituiran s:
(i) dvije ili tri skupine -NR6R7, ili
(ii) dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine; i
alkilna ili cikloalkilna skupina može biti neovisno supstituirana s jednim ili više supstituenata koje se bira između -C1-10 alkila, poput -C1-4 alkila, halogena, -CN, -NO2, -CF3, -C(O)R10, -NR10C(O)R10, -OCF3, -CON(R10)2, -COOR9, -OCOR10, -NR10COOR10, -OCON(R10)2, -NR10CON(R10)2, -OR9, -SR9, -NR10SO2R10, -SO2N(R10)2 i -SO2R10, gdje je svaki -R9 neovisno -C1-10 alkil, poput -C1-4 alkila, a svaki -R10 je neovisno -H ili -C1-10 alkil, poput -C1-4 alkila, osim što alkil nije supstituiran s alkilom;
(IIb) koji je spoj formule (II) gdje:
-R5 je G-L2-L1-, a -G je C3-10 cikloalkil,
-L1- je kovalentna veza, C1-12 alkilen ili C2-10 heteroalkilen,
-L2- je kovalentna veza ili C4-12 heterociklilen,
uz uvjet da je -L2- kovalentna veza samo kada je -L1- C2-10 heteroalkilen, -R5 je supstituiran s:
(i) jednom, dvije ili tri hidroksilne skupine, ili
(ii) jednom, dvije ili tri skupine -NR6R7, ili
(iii) jednom ili dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine,
uz uvjet da su (i), (ii) i (iii) izborni supstituenti kada je -L1- C2-12 heteroalkilen koji sadrži dušik i/ili -L2- je C4-10 heterociklilen koji sadrži dušik, te
cikloalkilna skupina može biti neovisno supstituirana s jednim ili više supstituenata koje se bira između -C1-10 alkila, poput -C1-4 alkila, halogena, -CN, -NO2, -CF3, -C(O)R10, -NR10C(O)R10, -OCF3, -CON(R10)2, -COOR9, -OCOR10, -NR10COOR10, -OCON(R10)2, -NR10CON(R10)2, -OR9, -SR9, -NR10SO2R10, -SO2N(R10)2 i -SO2R10, gdje je svaki -R9 neovisno -C1-10 alkil, poput -C1-4 alkila, a svaki -R10 je neovisno -H ili -C1-10 alkil, poput -C1-4 alkila, osim što alkil nije supstituiran s alkilom; i
(IId) koji je spoj formule (II) gdje:
-R5 je D-L1-, gdje je D-L1- supstituiran s:
(i) jednom, dvije ili tri hidroksilne skupine, ili
(ii) jednom, dvije ili tri skupine -NR6R7, ili
(iii) jednom ili dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine;
-D je C4-10 heterociklil;
-L1- je kovalentna veza, C1-12 alkilen ili C2-12 heteroalkilen,
uz uvjet da su (i), (ii) i (iii) izborni supstituenti kada je -L1- C2-12 heteroalkilen koji sadrži dušik, te
heterociklilna skupina može biti neovisno supstituirana s jednim ili više supstituenata koje se bira između -C1-10 alkila, poput -C1-4 alkila, halogena, -CN, -NO2, -CF3, -C(O)R10, -NR10C(O)R10, -OCF3, -CON(R10)2, -COOR9, -OCOR10, -NR10COOR10, -OCON(R10)2, -NR10CON(R10)2, -OR9, -SR9, -NR10SO2R10, -SO2N(R10)2 i -SO2R10, gdje je svaki -R9 neovisno -C1-10 alkil, poput -C1-4 alkila, a svaki -R10 je neovisno -H ili -C1-10 alkil, poput -C1-4 alkila, osim što alkil nije supstituiran s alkilom,
uz uvjet da spoj formule (II) nije spoj u kojem -X- i R5 zajedno tvore l-α-aminokiselinu, poput Lys, Arg, Dap, Ser, Phe, Trp, Leu, Ala, α,γ-diaminomaslačne kiseline (Dab) ili α,β-diaminopropionske kiseline (Dap), izborno zajedno s Dgp i Abu.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je spoj spoj formule (IIg).
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je -R4, zajedno s karbonilnom skupinom i dušikom na položaju alfa u odnosu na ugljik na kojeg je vezan, Dap, poput l-Dap.
5. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je spoj spoj formule (IIa).
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je -R5 supstituiran s jednom, dvije ili tri skupine -NR6R7, poput jedne skupine -NR6R7.
7. Spoj u skladu s patentnim zahtjevom 5 ili patentnim zahtjevom 6, naznačen time što je -L1- C1-12 alkilen ili C2-12 heteroalkilen, primjerice gdje je -L1- C2-12 heteroalkilen, primjerice gdje je -L1- C2-6 heteroalkilen.
8. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je spoj spoj formule (IIe).
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što je -R5 supstituiran s:
(ii) jednom, dvije ili tri skupine -NR6R7, ili
(iii) jednom ili dvije skupine -NR6R7, te s jednom, dvije ili tri hidroksilne skupine.
10. Spoj u skladu s patentnim zahtjevom 8 ili patentnim zahtjevom 9, naznačen time što je -R5 G-L2-L1-, a -G je C2-12 alkil.
11. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je spoj spoj formule (IIc).
12. Spoj u skladu s patentnim zahtjevom 11, naznačen time što:
(i) -G je C2-12 alkil; i/ili
(ii) -R5 je supstituiran s dvije ili tri skupine -NR6R7.
13. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 2 do 12 kao i biološki prihvatljivo pomoćno sredstvo, uz moguće drugo aktivno sredstvo, poput jednog ili više aktivnih sredstava u skladu s patentnim zahtjevom 1.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 2 do 12 ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačeni time što su namijenjeni upotrebi u postupku liječenja ili profilakse.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 2 do 12 ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačeni time što su namijenjeni upotrebi u postupku liječenja ili profilakse mikrobne infekcije, a postupak može dodatno uključivati liječenje infekcije u kombinaciji s aktivnim sredstvom kojeg se bira iz skupine koju čine rifampicin, fuzidična kiselina, novobiocin, oksacilin, azitromicin, aztreonam, meropenem, tigeciklin, te ciprofloksacin, te njihove farmaceutski prihvatljive soli i solvati.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201309248A GB201309248D0 (en) | 2013-05-22 | 2013-05-22 | Compounds and combinations |
| GB201404301A GB201404301D0 (en) | 2014-03-11 | 2014-03-11 | Compounds and combinations |
| PCT/GB2014/051547 WO2014188178A1 (en) | 2013-05-22 | 2014-05-21 | Polymyxin derivatives and their use in combination therapy together with different antibiotics |
| EP14726731.4A EP2999711B1 (en) | 2013-05-22 | 2014-05-21 | Polymyxin derivatives and their use in combination therapy together with different antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220898T1 true HRP20220898T1 (hr) | 2022-10-14 |
Family
ID=50829204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220898TT HRP20220898T1 (hr) | 2013-05-22 | 2014-05-21 | Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10407467B2 (hr) |
| EP (1) | EP2999711B1 (hr) |
| JP (1) | JP6643758B2 (hr) |
| KR (1) | KR102354902B1 (hr) |
| CN (1) | CN105308065B (hr) |
| BR (1) | BR112015029309A2 (hr) |
| CA (1) | CA2939061C (hr) |
| DK (1) | DK2999711T3 (hr) |
| ES (1) | ES2923762T3 (hr) |
| HK (1) | HK1221474A1 (hr) |
| HR (1) | HRP20220898T1 (hr) |
| HU (1) | HUE059544T2 (hr) |
| LT (1) | LT2999711T (hr) |
| PL (1) | PL2999711T3 (hr) |
| PT (1) | PT2999711T (hr) |
| RS (1) | RS63484B1 (hr) |
| RU (1) | RU2730012C2 (hr) |
| SI (1) | SI2999711T1 (hr) |
| TW (1) | TWI665218B (hr) |
| WO (1) | WO2014188178A1 (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012338571B2 (en) | 2011-11-18 | 2016-06-16 | New Pharma Licence Holdings Limited | Polymyxin derivatives |
| DK2999711T3 (da) | 2013-05-22 | 2022-07-18 | Spero Therapeutics Inc | Polymyxin-derivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika |
| WO2015031579A2 (en) * | 2013-08-28 | 2015-03-05 | The Medicines Company | Methods for treating bacterial infections using oritavancin and polymyxins |
| RS63138B1 (sr) * | 2014-03-11 | 2022-05-31 | Spero Therapeutics Inc | Derivati polimiksina i njihova upotreba u kombinovanoj terapiji zajedno sa različitim antibioticima |
| WO2016100578A2 (en) | 2014-12-16 | 2016-06-23 | Micurx Pharmaceuticals, Inc. | Antimicrobial polymyxins for treatment of bacterial infections |
| FI126143B (en) | 2015-01-15 | 2016-07-15 | Northern Antibiotics Oy | Polymyxine derivative and its uses |
| US9763996B2 (en) | 2015-01-16 | 2017-09-19 | Northern Antibiotics, Ltd. | Polymyxin derivative and uses thereof |
| KR101790296B1 (ko) * | 2015-03-26 | 2017-10-26 | 한국생명공학연구원 | 네트롭신을 유효성분으로 포함하는 그람음성 세균에 대한 폴리믹신의 항균 활성을 증가시키는 조성물 |
| WO2016166103A1 (en) * | 2015-04-13 | 2016-10-20 | Xellia Pharmaceuticals Aps | Polymyxin derivatives |
| JP7367950B2 (ja) * | 2015-09-29 | 2023-10-24 | モナッシュ ユニバーシティ | 抗菌性ポリミキシン誘導体化合物 |
| WO2018035183A1 (en) * | 2016-08-16 | 2018-02-22 | University Of Rochester | Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics |
| CN106631902A (zh) * | 2016-09-23 | 2017-05-10 | 上海步越化工科技有限公司 | 一种特拉万星侧链癸基(2‑氧代乙基)氨基甲酸9h‑芴‑9‑甲基酯的制备方法 |
| US11191773B2 (en) | 2017-07-17 | 2021-12-07 | President And Fellows Of Harvard College | Methods of treatment for bacterial infections |
| WO2019085926A1 (zh) * | 2017-10-31 | 2019-05-09 | 上海医药工业研究院 | 多黏菌素类似物及其制备方法 |
| WO2019084628A1 (en) | 2017-11-02 | 2019-05-09 | The University Of Queensland | Peptide antibiotics |
| US11713335B2 (en) | 2018-03-12 | 2023-08-01 | President And Fellows Of Harvard College | Aminocoumarin compounds and methods of their use |
| MX2020013811A (es) | 2018-06-25 | 2021-03-09 | Spero Therapeutics Inc | Compuestos. |
| CN111690040A (zh) * | 2019-03-12 | 2020-09-22 | 上海来益生物药物研究开发中心有限责任公司 | 多粘菌素衍生物、其制备方法和应用 |
| CN110179967A (zh) * | 2019-05-28 | 2019-08-30 | 中国医药集团总公司四川抗菌素工业研究所 | 多粘菌素母核和一种抗生素的组合物及其应用 |
| US20230141981A1 (en) | 2020-01-21 | 2023-05-11 | Shanghai Micurx Pharmaceuticals Co., Ltd | Novel compounds and composition for targeted therapy of kidney-associated cancers |
| US20230233590A1 (en) * | 2020-07-02 | 2023-07-27 | Purdue Research Foundation | Inhalation formulations of antimicrobial compounds |
| WO2022098950A1 (en) | 2020-11-06 | 2022-05-12 | Spero Therapeutics, Inc. | Compounds |
| EP4289272A4 (en) * | 2021-02-02 | 2024-07-17 | Korea Res Inst Bioscience & Biotechnology | ANTIMICROBIAL ADJUVANT CONTAINING A COMPOUND DERIVED FROM BIPHENYL AS ACTIVE INGREDIENT, AND USES THEREOF |
| KR20240035513A (ko) | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | 항바이러스 화합물 |
| WO2024003042A1 (en) | 2022-06-28 | 2024-01-04 | Breakthrough Biotech Drift Aps | Novel combinations of sesquiterpene alcohols, polymyxins and nisin compounds as antimicobial and/or antifungal compounds |
| WO2024105689A1 (en) * | 2022-11-14 | 2024-05-23 | Cipla Limited | Novel ophthalmic composition |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2128617A (en) | 1982-10-06 | 1984-05-02 | Martti Vaara | Polypeptides for use in antibacterial therapy |
| AU7753787A (en) | 1986-08-06 | 1988-02-24 | Jean-Luc Fauchere | Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b |
| US20010021697A1 (en) | 1987-09-14 | 2001-09-13 | Henning Lowenstein | Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components |
| TW274552B (hr) | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| JP4583559B2 (ja) * | 2000-07-24 | 2010-11-17 | 栄研化学株式会社 | Ｍｒｓａスクリーニング用培地 |
| CN1886128A (zh) | 2003-09-30 | 2006-12-27 | 柯西有限公司 | 用于治疗灼伤的组合物及方法 |
| US20060004185A1 (en) | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| WO2008001773A1 (en) | 2006-06-27 | 2008-01-03 | Toyo Tire & Rubber Co., Ltd. | Run flat tire |
| DK2057185T3 (en) * | 2006-08-11 | 2016-06-13 | Northern Antibiotics Oy | POLYMYXIN DERIVATIVES AND APPLICATIONS THEREOF |
| US8193148B2 (en) | 2008-02-08 | 2012-06-05 | Northern Antibiotics Ltd. | Short fatty acid tail polymyxin derivatives and uses thereof |
| FI20085469A0 (fi) | 2008-02-08 | 2008-05-16 | Northern Antibiotics Oy | Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä |
| US8329645B2 (en) | 2008-02-08 | 2012-12-11 | Northern Antibiotics Ltd. | Polymyxin derivatives and uses thereof |
| ES2334547B1 (es) | 2008-09-10 | 2010-12-03 | Universidad De Barcelona | Compuestos peptidicos antibacterianos. |
| WO2010075416A1 (en) | 2008-12-23 | 2010-07-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| JP5493387B2 (ja) * | 2009-02-25 | 2014-05-14 | 国立大学法人 東京大学 | 選択培地の製造方法及びその利用 |
| CN101851270A (zh) | 2009-04-03 | 2010-10-06 | 梁浩 | 一种多粘菌素衍生物及其制备方法 |
| WO2010130007A1 (en) | 2009-05-14 | 2010-11-18 | Monash University | Antimicrobial compounds |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2012051663A1 (en) | 2010-10-21 | 2012-04-26 | Monash University | Antimicrobial compounds |
| US9226786B2 (en) * | 2011-03-22 | 2016-01-05 | Lexion Medical Llc | Medical devices for clearing a surgical site |
| WO2012168820A1 (en) | 2011-06-08 | 2012-12-13 | Pfizer Inc. | Polymyxin derivatives useful as antibacterial agents |
| AU2012338571B2 (en) * | 2011-11-18 | 2016-06-16 | New Pharma Licence Holdings Limited | Polymyxin derivatives |
| DK2999711T3 (da) | 2013-05-22 | 2022-07-18 | Spero Therapeutics Inc | Polymyxin-derivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika |
| USRE48335E1 (en) | 2014-04-01 | 2020-12-01 | Monash University | Polymyxin derivatives as antimicrobial compounds |
-
2014
- 2014-05-21 DK DK14726731.4T patent/DK2999711T3/da active
- 2014-05-21 WO PCT/GB2014/051547 patent/WO2014188178A1/en active Application Filing
- 2014-05-21 RS RS20220760A patent/RS63484B1/sr unknown
- 2014-05-21 HU HUE14726731A patent/HUE059544T2/hu unknown
- 2014-05-21 BR BR112015029309A patent/BR112015029309A2/pt active Search and Examination
- 2014-05-21 CN CN201480029145.2A patent/CN105308065B/zh active Active
- 2014-05-21 SI SI201431984T patent/SI2999711T1/sl unknown
- 2014-05-21 KR KR1020157035048A patent/KR102354902B1/ko active IP Right Grant
- 2014-05-21 JP JP2016514479A patent/JP6643758B2/ja active Active
- 2014-05-21 PT PT147267314T patent/PT2999711T/pt unknown
- 2014-05-21 EP EP14726731.4A patent/EP2999711B1/en active Active
- 2014-05-21 LT LTEPPCT/GB2014/051547T patent/LT2999711T/lt unknown
- 2014-05-21 US US14/892,757 patent/US10407467B2/en active Active
- 2014-05-21 PL PL14726731.4T patent/PL2999711T3/pl unknown
- 2014-05-21 RU RU2015148032A patent/RU2730012C2/ru active
- 2014-05-21 ES ES14726731T patent/ES2923762T3/es active Active
- 2014-05-21 HR HRP20220898TT patent/HRP20220898T1/hr unknown
- 2014-05-21 TW TW103117787A patent/TWI665218B/zh active
- 2014-05-21 CA CA2939061A patent/CA2939061C/en active Active
-
2016
- 2016-08-10 HK HK16109519.5A patent/HK1221474A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160009041A (ko) | 2016-01-25 |
| ES2923762T3 (es) | 2022-09-30 |
| HUE059544T2 (hu) | 2022-11-28 |
| US10407467B2 (en) | 2019-09-10 |
| WO2014188178A9 (en) | 2015-01-08 |
| DK2999711T3 (da) | 2022-07-18 |
| TWI665218B (zh) | 2019-07-11 |
| US20160222061A1 (en) | 2016-08-04 |
| RS63484B1 (sr) | 2022-09-30 |
| CN105308065A (zh) | 2016-02-03 |
| EP2999711B1 (en) | 2022-06-29 |
| RU2730012C2 (ru) | 2020-08-14 |
| BR112015029309A2 (pt) | 2017-07-25 |
| CA2939061C (en) | 2023-10-24 |
| JP6643758B2 (ja) | 2020-02-12 |
| JP2016527186A (ja) | 2016-09-08 |
| SI2999711T1 (sl) | 2022-10-28 |
| WO2014188178A1 (en) | 2014-11-27 |
| EP2999711A1 (en) | 2016-03-30 |
| CA2939061A1 (en) | 2014-11-27 |
| PT2999711T (pt) | 2022-07-29 |
| TW201444876A (zh) | 2014-12-01 |
| CN105308065B (zh) | 2021-10-15 |
| LT2999711T (lt) | 2022-09-12 |
| HK1221474A1 (zh) | 2017-06-02 |
| PL2999711T3 (pl) | 2022-09-26 |
| KR102354902B1 (ko) | 2022-01-24 |
| RU2015148032A (ru) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220898T1 (hr) | Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima | |
| JP2016527186A5 (hr) | ||
| US11628200B2 (en) | Glycopeptide compositions | |
| NO20050205L (no) | Veksthormon frigjorende peptider | |
| EP3200781A1 (en) | Abietane-type diterpenoids | |
| BRPI0917315B8 (pt) | anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo | |
| JP2013155195A5 (hr) | ||
| JP2016525343A5 (hr) | ||
| RU2012108874A (ru) | Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы | |
| PE20110344A1 (es) | Derivados de etanodiamida como inhibidores de la integrasa del vih | |
| CA2968902A1 (en) | Compounds derived from polymyxin | |
| EP2588491A4 (en) | NEW PEPTIDE AND ITS USE | |
| HRP20220387T1 (hr) | Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima | |
| WO2018051102A1 (en) | Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent | |
| AR090439A1 (es) | Lipopeptidos antimicrobianos cortos | |
| WO2021042039A1 (en) | Synthetic antimicrobial peptides | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| MY187022A (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
| AR063140A1 (es) | Nuevo peptido de actinomadura nambiensis | |
| KR930019690A (ko) | 베타-아미노산의 신규 유도체 | |
| RU2018106490A (ru) | Комбинированные виды терапии | |
| CN114585316A (zh) | 骨结合化合物 | |
| RU2013102588A (ru) | Новые октапептидные соединения и их терапевтическое применение | |
| AR096370A1 (es) | Derivados de polimixina para el tratamiento de infecciones bacterianas | |
| SV2001000093A (es) | Formas polimorfas de un citrato de azobiciclo 2,2,2, octan-3-amina y sus composiciones farmaceuticas ref.pcl0216/82962/bb |